ERBB2 and non-small cell lung carcinoma: In combination with cytotoxic drugs bevacizumab is indicated in treatment of metastatic colorectal cancer [35], non-small cell lung cancer [36] and metastatic HER2-negative breast cancer [37], and recently as single treatment of recurrent glioblastoma [9], [10].